Chengdu Olymvax Biopharmaceuticals Inc. A

The Sci-Tech Innovation Board Medical ETF Huaxia closed up 2.22% at 1.06 yuan, while the underlying SSE STAR Market Biomedical Index surged 2.38%. Among constituents, Medicilon rose 12.77%, Olymvax Biopharmaceuticals gained 11.54%, and YD Bio advanced 8.49%. Recent policy tailwinds continue to unfold, including optimized review and approval for cell and gene therapies and the initial inclusion of drugs in medical insurance and commercial insurance catalogues. Meanwhile, domestic innovative drug overseas licensing deals approached 100 billion US dollars in the first half of the year, blockbuster new drugs received intensive approvals, and some pharmaceutical companies reported positive half-year earnings forecasts, steadily improving industry fundamentals. Donghai Securities noted that the pharmaceutical and biomedical sector offers significant medium- to long-term investment value and recommended active positioning.

The STAR Market Healthcare ETF Huaxia rose 3.86% to 1.08 yuan, with net inflows for 10 consecutive days, attracting a total of 135 million yuan. The SSE STAR Market Biomedical Index surged 3.93%, with constituent stocks Medici rising 15.28%, Yundong Biotech up 11.44%, and Olin Biotech up 10.38%. In news, the National Essential Medicines List 2026 edition added 165 new drugs, and in the first half of 2026, the total value of China's innovative drug out-licensing deals approached the 100 billion dollar mark. Nanjing Securities noted that with the upcoming WCLC and ESMO conferences, cutting-edge fields such as bispecific antibodies and antibody-drug conjugates will enter a period of intensive clinical data disclosure, accelerating the alignment of China's innovative drug valuation system with global standards.

China's first ultrasound brain-computer interface company Gestalt Tech has completed a 420 million yuan angel+ round of financing. This round was led by Huaying Capital, with follow-on investments from C Capital, Sequoia China, Lens Technology, China Electronics Health Fund, Sinovation Ventures, Lingang Sci-Tech Innovation Investment, Fudan Furong Capital, and Guotai Venture Capital, among other leading domestic and international investment institutions. Existing shareholders including Daotong Investment, Yunshi Capital, Qingsong Capital, and Gobi Partners continued to oversubscribe. China Renaissance acted as the exclusive financial advisor. At the same time, Gestalt Tech's Shanghai headquarters in the Brain Intelligence Park in Minhang District was officially inaugurated. As of 14:18 on July 3, 2026, the Shanghai Stock Exchange STAR Biomedical Index rose strongly by 2.69 percent. Among constituent stocks, MGI Tech rose 14.97 percent, Dizal Pharmaceutical rose 10.77 percent, and Olym Biotech rose 8.82 percent, with stocks like Youcare Pharmaceutical and Yundong Biotech also rising. The STAR Medical ETF Huaxia rose 2.17 percent, heading for a fifth consecutive gain, with the latest price at 1.08 yuan. CICC believes that innovative fields represented by AI plus healthcare and brain-computer interfaces are experiencing rapid development, with systems from supporting policies to capital support gradually improving, and such directions may present structural investment opportunities.

The Sci-Tech Innovation Board Medical ETF Huaxia rose 0.66%, heading for a fifth straight gain, with the latest price at 1.07 yuan. As of 1:49 PM on July 3, 2026, the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index surged 1.11%, with constituent Olin Bio up 8.77%, Dizal Pharmaceutical up 7.79%, and MGI Tech up 6.57%. In related news, the 12th round of national centralized drug procurement explicitly includes only mature generics, while innovative drugs still under patent protection are excluded, signaling a policy shift from cost control and price cuts to supporting and strengthening the industry. Zhongtai Securities noted that the pharmaceutical sector's valuation attractiveness and defensive attributes are prominent, with signs of bottoming and recovery emerging at the end of June, especially in CXO and innovative drugs, and recommended focusing on the internationalization of innovative drugs and CRO/CDMO performance delivery targets. The Sci-Tech Innovation Board Medical ETF Huaxia closely tracks the Shanghai Stock Exchange Sci-Tech Innovation Board Biomedical Index, which selects 50 listed companies in biomedical and related fields on the Sci-Tech Innovation Board as samples, with the top ten holdings accounting for 51.84% of the total.